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By disease: ischemic heart disease, 1.9 times or 10 days longer; hypertension 1.3 times 
or 4 days longer; congestive heart failure, 1.2 times or 3 days longer; and rheumatoid 
arthritis, 1.4 times or 2 days longer. Obese patients with diabetes and s/p cerebral 
vascular accident had a shorter LOS (0.8 times or 3 days, and 0.8 times or 4 days 
respectively). CONCLUSIONS: Obesity increases the LOS for all-cause hospital admis-
sions among patients with various underlying chronic diseases. This may be due to 
insufficient diagnosis by the primary provider or specialist, inadequate medication 
dosing (eg, pain management), or inadequate support during an inpatient stay. A 
proactive health care policy is needed to guide the management of patients with 
chronic disease who are also obese, with the potential for cost-savings of interven-
tional, pharmaceutical, or surgical treatment of obesity at baseline.
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OBJECTIVES: The aim of the present analysis was to identify the level of the availabil-
ity and total expenditure of medicines for rare diseases with European authorization 
and orphan designation. In Poland all innovative medical technologies and services 
claiming public money founding have to be assessed by Agency for Health Technology 
Assessment (AOTM). Pharmacoeconomic evaluations of new therapies are required 
for all reimbursement decisions and orphan drug manufacturers cannot be exempted 
from providing a full pharmacoeconomic or HTA reports. The criteria of assessment 
connected with clinical and cost effectiveness (threshold is 3xGDP for ICUR/QALY) 
are the same for all kind of drugs. METHODS: All orphan designation admitted by 
European Medicines Agency (EMA) until the end of 2014 were reviewed and analyzed 
from the official website of EMA. Among 792 EMA’s orphan registrations studied 78 
(9,8%) applied to orphan drugs. We compared the outcomes with reimbursement list 
officially published by Ministry of Health. Then it was checked what was the share of 
orphan drugs in overall reimbursement spending. RESULTS: At the end of 2014 there 
were 28 orphan drugs available on the reimbursement list (36% of designed by EMA). 
The total public payer reimbursement spending was € 2.41bn in 2012 and € 2.26bn in 
2013. Orphan drugs have only accounted for a small percentage of the overall drug 
budget in polish health care system (1,5% in 2012 and 3,2% in 2013). CONCLUSIONS: 
In the literature we can find opinions that the relatively low budget impact of orphan 
drugs is often used as an argument in reimbursement decisions. In Poland reimburse-
ment was awarded to the minority of orphan drugs designed by EMA. Very strict 
requirements in order to ensure compatibility with law directives could potentially 
influence negative reimbursement decisions for orphan drugs.
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BACKGROUND: Obesity is a pathology that leads to several co-morbidities such as 
diabetes and hypertension. In Brazil obesity rates (BMI > 30kg/m2) raised from 11.8% 
in 2006 to 17.5% in 2013. Bariatric Surgery is the most effective treatment to achieve 
excess weight lost for morbid patients. It is estimated that Brazil has around 1.8 
million people with BMI > 40kg/m2, considering that Brazil has an universal health 
care system and 25% of the population relies in the private health care sector, sev-
eral people are eligible to get bariatric surgery OBJECTIVES: Evaluate the use of the 
resources dedicated to treat morbid obese patients in the Brazilian public health 
care system (SUS) from 2008 to 2013 METHODS: Revised data of expenditures, num-
ber of surgeries and length of stay related to bariatric surgery in the database of the 
IT Department of SUS (DATASUS) RESULTS: The number of certified hospitals that 
perform bariatric surgery increased by 35% and the percentage of states covered 
by certified hospitals rose from 60% to 74%. During the same period the number of 
procedures increased by 113%. Despite the increase in the number of procedures 
by 113%, the days of hospitalization required for surgeries increased only 52%; this 
is due the average length of stay reduction from 5.7 days to 4.1 days, showing a 
better efficiency among hospitals. The total expenditure in bariatric surgeries rose 
by 161%. CONCLUSIONS: Analysis demonstrated that the access to the bariatric 
procedure in Brazil has increased in the past five years. The hospitals’ efficiency 
improved during the same period, decreasing the average length of stay. Today 
the Brazilian public health care system provides surgery to less than 0.75% of the 
eligible population and despite the access increase; more resources (physicals and 
infrastructure) are needed in order to treat the morbid obese population
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OBJECTIVES: To describe treatment patterns and cost in patients with PSO (psoria-
sis) receiving biologic therapies (BT). METHODS: A retrospective cohort of medica-
tion claims data from IMS Brogan Private (Canadian national) and Public (Ontario 
and Quebec) Drug Plan databases was analysed. Biologic-naïve PSO patients > 18 
years of age were selected between 01/01/2007 and 03/30/2011 and followed for 
24 months to understand lines of therapy, retention on BT, and annual therapy 
costs. Target biologics included adalimumab, etanercept, infliximab and usteki-
numab. RESULTS: 3,546 patients were identified. Of those, 44% initiated etanercept, 
26% adalimumab, 19% ustekinumab, and 10% infliximab. 32% of patients remained 
on 1st line therapy, 16% switched, and 52% stopped therapy over the 24 month 
period. Median days on 1st line therapy was longer in public than private plans (502 
vs. 357). Of those who switched, 556 received 2 lines, and 105 received 3 or more lines 
of BT. In a retention model of private plan patients, those who supplemented with 
non-biologic PSO therapies were 16% - 42% more likely to stay on BT than those tak-
the induction period for each drug. Overall, 63% of patients experienced a dose 
escalation, of which 68% occurred within the first year, excluding induction. Peak 
frequency of dose escalation occurred between weeks 11-30. Calculated daily, esca-
lated dose was greater than maintenance by 9% for adalimumab, 14% for etanercept, 
and 28% for ustekinumab. CONCLUSIONS: Across all treatments, dose escalation 
was recorded in over 60% of patients, most often in the first year of treatment, 
indicating that patients may require additional doses to maintain response. These 
data highlight the need for new treatments which provide high sustained efficacy, 
with a rapid onset of action.
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OBJECTIVES: To quantify the effect of the implementation of Florida’s PMP and 
pill mill laws on overall and high risk opioid prescribing, utilization, and dispens-
ing. METHODS: We applied comparative interrupted time series analyses to IMS 
Health LRx LifeLink data to characterize the effect of PMP and pill mill law imple-
mentation on a closed cohort of patients, prescribers and retail pharmacies between 
July 2010 and Sept 2012 in Florida (intervention state) compared with Georgia (con-
trol state). We conducted numerous sensitivity analyses including varying the 
length of observation and modifying requirements for continuous observation of 
individuals throughout the study period. RESULTS: From July 2010 to September 
2012, a cohort of 2.6 million patients, 431,890 prescribers and 2,829 pharmacies was 
associated with approximately 480 million prescriptions in Florida and Georgia, 
8% of which were for opioids. Average total monthly opioid volume (355.1 vs. 124.2 
kilograms [kg]), average dose per transaction (55.2 vs. 46.6 milligrams [mg] MEDD), 
and average number of days supply (18.4 vs. 16.0 days) were each higher in Florida 
than Georgia prior to implementation of Florida’s PMP and pill mill laws. Overall, 
Florida’s laws were associated with statistically significant declines in opioid volume 
(3.7 kilograms/month) and MEDD (0.46 mg/month), without any change in days 
supply. Reductions were limited to prescribers and patients with the highest base-
line opioid prescribing and utilization, respectively. Sensitivity analyses varying the 
time windows and enrollment criteria supported the main results. CONCLUSIONS: 
Implementation of PMP and pill mill laws in Florida was associated with decreases 
in prescription opioid dispensing relative to Georgia among patients and providers 
with high levels of opioid utilization at baseline.
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OBJECTIVES: Hemophilia is an inherited condition requiring lifelong, expensive 
treatment. Initiating prophylaxis treatment with factors VIII (hemophilia A) or 
IX (hemophilia B) at an early age has been shown to be effective in improving 
health outcomes. In 2007 the medical advisory council of the National Hemophilia 
Foundation (NHF’s MASAC) recommended prophylaxis treatment as the optimal 
therapy for these patients. The study objectives were:(1) To explore the economic 
burden over the patient’s lifespan; (2) To quantify changes in factor VIII/IX utilization 
and related costs over the past decade. METHODS: A retrospective, US health insur-
ance claim database (2004-2012) analysis was conducted. Males with ≥ 2 pharmacy 
claims for a hemophilia drug within 3 months, and continuous enrollment for ≥ 180 
days were included. Patients utilizing inhibitor treatments were excluded. Annual 
payer and patient out-of-pocket (OOP) expenses were calculated by service category 
(inpatient, outpatient, medications), and stratified by patient’s age and calendar 
year. Costs were adjusted to 2013USD. Annual supply days (ASD) per patient were 
calculated; ASDs over time were compared using a t-test. RESULTS: For hemophilia 
A (N= 727), increase in payers’ costs was observed during the first 4 decades of life, 
peaking at age 34 ($273,669) decreasing thereafter, and annual OOP staying constant 
at $2,589/year. For hemophilia B (N= 161), an increase in payers’ costs was observed 
during the first 3 decades of life peaking at age 29 ($281,981) decreasing thereafter 
with annual OOP at $2,401/year. Between 2007 and 2012, ASD per patient increased 
significantly for both factor VIII (ADVATE®: 160.5 vs. 249.9 days, p= 0.00029) and 
factor IX (BENEFIX®: 132.8 vs. 214.7 days, p= 0.0255) coinciding with payers’ drugs 
cost over the same time period. (Hemophilia A: $186,283 to $212,747respectively; 
hemophilia B: $147,778 to $186,851 respectively). CONCLUSIONS: Over the past dec-
ade, the mean per patient consumption of factor replacement therapy has increased 
substantially, in line with new treatment guidelines.
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OBJECTIVES: An obese body mass index (BMI) increases morbidities, however there 
are few chronic disease registries that can quantify the cost of obesity. Clalit Health 
Services (CHS), with complete longitudinal data of over 4 million members, provides 
an ideal format for comparing health care utilization between obese and non-obese 
patients to inform the need for improved health care policy. METHODS: For the years 
2011-2013 inclusive, we took two random samples of 10,000 obese (BMI> 30) patients 
and 10,000 normal and underweight (BMI< = 25) from the CHS database both accord-
ing to Clalit population age standard. We then extracted their additional chronic 
diseases from the CHS registry. Finally, we compared the average length of stay (LOS) 
for inpatient admissions between the groups, by disease. RESULTS: Obese patients 
with underlying chronic disease had, on average, a 27% increased LOS compared to 
non-obese patients with chronic disease. The greatest effect was seen among obese 
patients with chronic renal failure, whose LOS was 2.7 times or nearly 20 days longer. 
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only reviewed oncology orphans thereby resulting in inconsistent access. Alternative 
funding mechanisms sometimes provide a temporary reimbursement fix in the UK. 
Ex- factory pricing varied by country both at launch and over time. CONCLUSIONS: 
Significant differences exist between the number of orphan drug approvals and 
time to access in the US vs. EU. The US is notably faster than the EU5 and Germany 
is notably faster than other EU5 countries. For pricing, the US is not always the high 
price country. Furthermore, there appears to be an inverse relationship between size 
of the indicated patient population and reimbursed price.
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OBJECTIVES: To explore use of electronic medical records (EMR) for identifying driv-
ers of all-cause healthcare resource utilization and factors associated with increased 
resource use in patients with fibromyalgia (FM). METHODS: This retrospective 
analysis used structured de-identified EMR data from the Humedica database 
including demographics, clinical characteristics, healthcare resource utilization, 
and prescriptions. Adults (≥ 18 years) with FM were identified based on ≥ 2 ICD-9 
codes for FM (729.1) ≥ 30 days apart between January 1, 2008 and December 31, 2012, 
and were required to have ≥ 12 months continuous enrollment pre- and post-index; 
the first FM diagnosis was the index event. Multivariate analysis using generalized 
linear models evaluated how demographic and clinical characteristics relate to 
12-month post-index resource utilization. RESULTS: Patients were predominantly 
female (81.4%), Caucasian (87.7%), with a mean±SD age of 54.4±14.8 years. Primary 
drivers of resource utilization were “medication orders” and “physician office visits,” 
used by 91.6% and 87.5% of patients, respectively, with 12-month post-index means 
of 21±21.5 drug orders/patient and 15.1±18.1 office visits/patient, the latter account-
ing for 73.3% of all healthcare visits. Opioids were the most common prescrip-
tion medication, 44.3% of patients. The chance of being a high healthcare resource 
utilizer was significantly increased (p< 0.001) 1.26-fold among African-Americans 
relative to Caucasians and for patients with specific comorbid conditions ranging 
from 1.06-fold (musculoskeletal pain and depression/bipolar disorder) to 1.21-fold 
(congestive heart failure). Similarly, factors significantly (p< 0.001) associated with 
increased number of medications ordered included being female (1.23-fold) and 
the presence of conditions such as sleep disorders (1.08-fold), depression/bipolar 
disorder (1.07-fold), and anxiety (1.06-fold). CONCLUSIONS: Physician office visits 
and pharmacotherapy were drivers of all-cause healthcare utilization; opioids were 
the most commonly prescribed medication class. Comorbid conditions were key 
factors associated with high resource use. EMR can be a useful tool for identifying 
and potentially managing FM patients with high healthcare resource utilization.
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OBJECTIVES: In this context, the challenge of this essay is to estimate the price elas-
ticity for soda and fruit drink in Brazil and the price effects on weight outcomes 
and obesity prevalence. METHODS: The elasticity was measured through a two-part 
model (TPM) estimated for all sample and different subgroups. The empirical model 
explains the quantities of SSB demanded as function of its prices and other variables. 
Considering the estimated elasticity, we converted the reduction on consumption into 
weight transforming the consumption elasticity from grams to kilocalories and then 
we applied a frequently used rule, which considers that a reduction of 3,500 calories 
induces a 0,450 kg loss in body weight, everything else remaining equal. RESULTS: 
Overall, the results display a smaller prevalence and lower consumption with higher 
prices. The TPM model predicts a reduction of 348.3g in weekly soda consumption 
and 4.5g of fruit drink to each one Real increased price. For all sample estimates, price 
elasticity is -0.61 for soda and -1.32 for fruit drinks, suggesting that a 20% increase in 
price was associated with a decline of soda and fruit drink in weekly consumption 
by 12.2% and 26.4%, respectively. This evidence shows a higher sensitivity to price 
changes for juice drinks than for soda, in spite of the higher consumption of soda. 
TConsidering that weight reductions, the prevalence of overweight among adults 
could decline from 48.13 to 47.75 percent and obesity prevalence could be reduced 
from 18.77 to 18.5 percent in one year. CONCLUSIONS: Our main findings suggest that 
tax policy might be an effective tool to reduce the soda and juice drink consumption 
and body weight. We also identified that subgroups who consume higher amounts 
of SSB are relatively more price sensitive and in these cases pricing policies have an 
expressive potential in reducing SSB consumption and body weight.
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OBJECTIVES: In 2006, the American College of Medical Genetics (ACMG) recom-
mended expanding NBS, relying largely on scoring from a stakeholder survey on 
19 attributes of 84 rare conditions. Points were scored according to mean answers 
from the responders. Sums of scores resulted in 3 different entry points into an 
algorithm (EPA) that determined ACMG final screening recommendations. This 
research examines one of the survey questions about condition incidence and 
compares the ACMG use of surveyed opinions versus the actual facts that they 
also report. METHODS: The report indicated each condition’s mean scores for 
survey questions. The incidence question scored 0-100 points. Very rare conditions 
ing BT alone (P< 0.001); patients receiving non-PSO concomitant medications were 
19% - 32% more likely to stay on their BT (p< 0.001) than those not receiving; and 
patients who switched BT were 2.35x more likely to stop BT within 24 months versus 
non-switchers (p< 0.001). Using a cost model, patients who switched BT had higher 
average annual costs of $4,355 and $3,679 in private and public plans respectively 
compared to those who didn’t switch (P< 0.001). CONCLUSIONS: 68% of PSO patients 
on BT either switch or stop therapy, indicating there remains an unmet need for 
new treatment options. In addition, switching is associated with significantly higher 
therapy costs. With better understanding of predictors for retention, patient support 
programs can be designed to address the specific needs of at-risk groups.
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OBJECTIVES: Both ultra orphan and cancer drugs are premium priced therapies with 
high annual per patient costs. The local legislation and reimbursement mechanisms 
have had significant impact on pricing trends for these therapies. The objectives 
of this analysis were to compare the price differential for ultra orphan and cancer 
drugs in the US and the UK, and understand the impact of local reimbursement 
mechanisms. METHODS: A set of 22 drugs (10 ultra orphan and 12 cancer drugs) 
was selected based on their availability in the US and the UK. The 2014 AWP, WAC 
and net prices were obtained for all 22 drugs. All UK prices were converted to USD. 
Primary discussions with ex-payer and policy experts were conducted to understand 
the basis and implication of the price differentials. RESULTS: For ten selected ultra 
orphan drugs, the median WAC price premium for the US compared to the UK net 
price was 10%. For 12 selected cancer drugs the median WAC price premium for 
the US compared to the UK net price was 106% (based on AWP the premiums were 
29% and 149%, respectively). Eight out of 10 ultra orphan and 12 out of 12 cancer 
drugs were higher priced in the US compared to the UK. Primary discussions with 
experts suggest the role of legislation for coverage of cancer drugs in the US and 
special coverage of rare disease products in the UK and reimbursement mechanisms 
(use of cost effectiveness driven HTAs in the UK and the use of co-pay in the US) 
as primary drivers of high price differential for cancer drugs versus ultra orphan 
therapies. CONCLUSIONS: The local reimbursement mechanisms are major driv-
ers of price differential for ultra orphan and cancer drugs in the US and the UK.
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OBJECTIVES: Pharmaceutical manufacturers can apply to the US Food and Drug 
Administration (FDA) and the European Medicines Agency (EMA) for orphan drug 
status for pharmaceuticals that treat rare medical conditions. This study compares 
the policies and processes that influence orphan drug designation in the US and the 
EU and examines the approval data to explain any differences and/or trends in deci-
sion making. METHODS: We conducted a quantitative analysis on the publicly avail-
able data on orphan drug approvals released by the FDA and EMA. By looking at the 
numbers of drugs approved each year, the drugs submitted and approved for orphan 
indications, and their relevant disease areas we were able to identify any trends 
and dissimilarities in the organizations final approval decisions. Following this, 
we performed qualitative research with a focused literature search of the Medline 
database and relevant websites, to explore the differences in policies and processes 
between the organizations that may have led to conflicting decisions. RESULTS: 
There were significant differences in the processes, policies and requirements for 
orphan drugs. The FDA consistently approved more orphan drugs each year dur-
ing 2002-2014 (when comparison data were available). However, the numbers of 
products accepted are converging (e.g. in 2005, the EMA approved approximately 
81% fewer orphan drugs; by 2013, this gap was 36%). Some differences in decisions 
were identified, largely due to different evidence requirements. CONCLUSIONS: 
The likelihood of a drug gaining orphan drug status in either the US or the EU is 
dependent on a number of different factors. If the trends persist, it is likely that the 
organizations will designate a similar number of products as orphan drugs each 
year, although the approved products may differ. These may affect which organiza-
tion manufacturers choose to submit applications to first.
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OBJECTIVES: To examine pricing, reimbursement and market access of orphan drugs 
approved by EMA and FDA between January 2009 and December 2013. METHODS: 
Analyzed the orphan drugs approved by both EMA and FDA between Jan 2009 and 
Dec 2013, by country (US & EU5) regarding; time to market, benefit evaluations, 
pricing and reimbursement differences, as well as any similarities or differences by 
size of population. RESULTS: In the time frame, 102 orphan drugs were approved in 
the US vs. just 31 by the EMA. Of those, only 13 orphan drugs were approved by both 
agencies. For these 13 drugs, approval took an average of 66 weeks from filing with 
the EMA and 45 weeks with the FDA. Average US time to launch from approval was 9 
weeks (only 2 weeks if one outlier is removed). In the EU, all 13 drugs were available 
and reimbursed on the German market in an average of 16 weeks while only 5 had 
completed P&R in Spain in an average of 97 weeks. Early access to reimbursement 
via the ATU program in France and L648 program in Italy was sometimes pursued. 
In the UK, SMC recommendations for orphan drugs were often negative, and NICE 
